Cargando…

Study Protocol: Understanding SARS-Cov-2 infection, immunity and its duration in care home residents and staff in England (VIVALDI)

Global infection and mortality rates from severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) are disproportionately high in certain populations, including amongst older people. Care home residents are frequently exposed to infection due to contact with staff and other residents, and are hi...

Descripción completa

Detalles Bibliográficos
Autores principales: Krutikov, Maria, Palmer, Tom, Donaldson, Alasdair, Lorencatto, Fabiana, Forbes, Gill, Copas, Andrew, Robson, James, Hopkins, Susan, Moss, Paul, Farrar, Jeremy, Hayward, Andrew, Shallcross, Laura
Formato: Online Artículo Texto
Lenguaje:English
Publicado: F1000 Research Limited 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7851710/
https://www.ncbi.nlm.nih.gov/pubmed/33564722
http://dx.doi.org/10.12688/wellcomeopenres.16193.2
_version_ 1783645680268476416
author Krutikov, Maria
Palmer, Tom
Donaldson, Alasdair
Lorencatto, Fabiana
Forbes, Gill
Copas, Andrew
Robson, James
Hopkins, Susan
Moss, Paul
Farrar, Jeremy
Hayward, Andrew
Shallcross, Laura
author_facet Krutikov, Maria
Palmer, Tom
Donaldson, Alasdair
Lorencatto, Fabiana
Forbes, Gill
Copas, Andrew
Robson, James
Hopkins, Susan
Moss, Paul
Farrar, Jeremy
Hayward, Andrew
Shallcross, Laura
author_sort Krutikov, Maria
collection PubMed
description Global infection and mortality rates from severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) are disproportionately high in certain populations, including amongst older people. Care home residents are frequently exposed to infection due to contact with staff and other residents, and are highly susceptible to infection due to their age and co-morbidity. In England, official statistics suggest that at least 25% of all deaths in care home residents since the start of pandemic are linked to coronavirus disease 2019 (COVID-19), but limited testing for SARS-CoV-2 early in the pandemic means estimates of the true burden of disease are lacking. Additionally, little is known about patterns of transmission between care homes, the community and hospitals, or the relationship between infection and immunity in care home staff and residents. The VIVALDI study plans to address these questions. VIVALDI is a prospective cohort study aiming to recruit  6,500 staff and 5000 residents from 105 care homes across England. Successive rounds of testing for infection will be performed over a period of 12 months.  Nasopharyngeal swabs will detect evidence of viral RNA and therefore active infection (accompanied by collection of data on symptoms), whereas blood tests will detect antibodies and evidence of cellular immunity to SARS-CoV-2. Whole genome sequencing of viral isolates to investigate pathways of transmission of infection is planned in collaboration with the COVID-19 Genomics UK Consortium. Qualitative interviews with care home staff will investigate the impact of the pandemic on ways of working and how test results influence infection control practices and behaviours. Data from residents and staff will be linked to national datasets on hospital admissions, antibody and PCR test results, mortality and care home characteristics.  Data generated will support national public health efforts to prevent transmission of COVID-19 and protect care home staff and residents from infection. Protocol registration: ISRCTN14447421 05/06/2020
format Online
Article
Text
id pubmed-7851710
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher F1000 Research Limited
record_format MEDLINE/PubMed
spelling pubmed-78517102021-02-08 Study Protocol: Understanding SARS-Cov-2 infection, immunity and its duration in care home residents and staff in England (VIVALDI) Krutikov, Maria Palmer, Tom Donaldson, Alasdair Lorencatto, Fabiana Forbes, Gill Copas, Andrew Robson, James Hopkins, Susan Moss, Paul Farrar, Jeremy Hayward, Andrew Shallcross, Laura Wellcome Open Res Study Protocol Global infection and mortality rates from severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) are disproportionately high in certain populations, including amongst older people. Care home residents are frequently exposed to infection due to contact with staff and other residents, and are highly susceptible to infection due to their age and co-morbidity. In England, official statistics suggest that at least 25% of all deaths in care home residents since the start of pandemic are linked to coronavirus disease 2019 (COVID-19), but limited testing for SARS-CoV-2 early in the pandemic means estimates of the true burden of disease are lacking. Additionally, little is known about patterns of transmission between care homes, the community and hospitals, or the relationship between infection and immunity in care home staff and residents. The VIVALDI study plans to address these questions. VIVALDI is a prospective cohort study aiming to recruit  6,500 staff and 5000 residents from 105 care homes across England. Successive rounds of testing for infection will be performed over a period of 12 months.  Nasopharyngeal swabs will detect evidence of viral RNA and therefore active infection (accompanied by collection of data on symptoms), whereas blood tests will detect antibodies and evidence of cellular immunity to SARS-CoV-2. Whole genome sequencing of viral isolates to investigate pathways of transmission of infection is planned in collaboration with the COVID-19 Genomics UK Consortium. Qualitative interviews with care home staff will investigate the impact of the pandemic on ways of working and how test results influence infection control practices and behaviours. Data from residents and staff will be linked to national datasets on hospital admissions, antibody and PCR test results, mortality and care home characteristics.  Data generated will support national public health efforts to prevent transmission of COVID-19 and protect care home staff and residents from infection. Protocol registration: ISRCTN14447421 05/06/2020 F1000 Research Limited 2021-01-29 /pmc/articles/PMC7851710/ /pubmed/33564722 http://dx.doi.org/10.12688/wellcomeopenres.16193.2 Text en Copyright: © 2021 Krutikov M et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Study Protocol
Krutikov, Maria
Palmer, Tom
Donaldson, Alasdair
Lorencatto, Fabiana
Forbes, Gill
Copas, Andrew
Robson, James
Hopkins, Susan
Moss, Paul
Farrar, Jeremy
Hayward, Andrew
Shallcross, Laura
Study Protocol: Understanding SARS-Cov-2 infection, immunity and its duration in care home residents and staff in England (VIVALDI)
title Study Protocol: Understanding SARS-Cov-2 infection, immunity and its duration in care home residents and staff in England (VIVALDI)
title_full Study Protocol: Understanding SARS-Cov-2 infection, immunity and its duration in care home residents and staff in England (VIVALDI)
title_fullStr Study Protocol: Understanding SARS-Cov-2 infection, immunity and its duration in care home residents and staff in England (VIVALDI)
title_full_unstemmed Study Protocol: Understanding SARS-Cov-2 infection, immunity and its duration in care home residents and staff in England (VIVALDI)
title_short Study Protocol: Understanding SARS-Cov-2 infection, immunity and its duration in care home residents and staff in England (VIVALDI)
title_sort study protocol: understanding sars-cov-2 infection, immunity and its duration in care home residents and staff in england (vivaldi)
topic Study Protocol
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7851710/
https://www.ncbi.nlm.nih.gov/pubmed/33564722
http://dx.doi.org/10.12688/wellcomeopenres.16193.2
work_keys_str_mv AT krutikovmaria studyprotocolunderstandingsarscov2infectionimmunityanditsdurationincarehomeresidentsandstaffinenglandvivaldi
AT palmertom studyprotocolunderstandingsarscov2infectionimmunityanditsdurationincarehomeresidentsandstaffinenglandvivaldi
AT donaldsonalasdair studyprotocolunderstandingsarscov2infectionimmunityanditsdurationincarehomeresidentsandstaffinenglandvivaldi
AT lorencattofabiana studyprotocolunderstandingsarscov2infectionimmunityanditsdurationincarehomeresidentsandstaffinenglandvivaldi
AT forbesgill studyprotocolunderstandingsarscov2infectionimmunityanditsdurationincarehomeresidentsandstaffinenglandvivaldi
AT copasandrew studyprotocolunderstandingsarscov2infectionimmunityanditsdurationincarehomeresidentsandstaffinenglandvivaldi
AT robsonjames studyprotocolunderstandingsarscov2infectionimmunityanditsdurationincarehomeresidentsandstaffinenglandvivaldi
AT hopkinssusan studyprotocolunderstandingsarscov2infectionimmunityanditsdurationincarehomeresidentsandstaffinenglandvivaldi
AT mosspaul studyprotocolunderstandingsarscov2infectionimmunityanditsdurationincarehomeresidentsandstaffinenglandvivaldi
AT farrarjeremy studyprotocolunderstandingsarscov2infectionimmunityanditsdurationincarehomeresidentsandstaffinenglandvivaldi
AT haywardandrew studyprotocolunderstandingsarscov2infectionimmunityanditsdurationincarehomeresidentsandstaffinenglandvivaldi
AT shallcrosslaura studyprotocolunderstandingsarscov2infectionimmunityanditsdurationincarehomeresidentsandstaffinenglandvivaldi